Skip to main content

TMDX TransMedics Group, Inc.

Healthcare

88.24 USD 1D +19.26 +27.92% Close 11/6
Since 2024-12-06 +1.1%

Close 11/6

Open
79.11
High
88.44
Low
76.50
Prev close
68.98
Volume
3.95M
Amplitude
17.31%
P/E
18.9
P/B
4.3
Revenue YoY (TTM)
+28.5%
52W 60.11 156.00
FinLab Studio

From TransMedics Group, Inc. to every stock like it

AI finds several complementary traits of TransMedics Group, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like TransMedics Group, Inc.

Is TransMedics Group, Inc. a buy? Fundamentals and valuation first

As of 2026-11-05

Quality: Good, Growth: Good, Risk / liquidity: Good; Valuation: Pricey, Momentum: Weak.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 18.9 51th percentile · Pricey
Price / book 4.4 81th percentile · Expensive
Free-cash-flow yield (%) 1.9 54th percentile · Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good ROE, TTM is Top; FCF margin, TTM is Good.
ROE, TTM (%) 26.2 86th percentile · Top
Operating margin, TTM (%) 11.9 59th percentile · Good
FCF margin, TTM (%) 6.1 54th percentile · Good
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top; Diluted EPS growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 28.5 80th percentile · Top
Diluted EPS growth, TTM YoY (%) 48.2 76th percentile · Good
Momentum Weak 60-day return is Average; 240-day return is Lagging.
60-day return (%) -20.7 31th percentile · Average
240-day return (%) -44.3 19th percentile · Lagging
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 70,109,399.0 84th percentile · Top
60-day annualized volatility (%) 46.5 50th percentile · Average
Factor Investing Explained: 10 Classic Factors in US Stocks

TransMedics Group, Inc. (TMDX) today

2 quant signals active · As of 2026-11-05

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

TransMedics Group, Inc. (TMDX) peers and tracking

Watchlist

This page refreshes daily after the close. Add TransMedics Group, Inc. to your watchlist to track signal changes on your next visit.

TransMedics Group, Inc. (TMDX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 28.5%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

8 historical occurrences (since 2019-08-08)

Average forward return after Filed revenue acceleration

20-day: Win 71.4%, Sample 7, Median +10.6%, Excess +12.7%, Beat mkt rate 71.4%

60-day: Win 57.1%, Sample 7, Median +21.3%, Excess +13.2%, Beat mkt rate 57.1%

120-day: Win 57.1%, Sample 7, Median +39.1%, Excess +33.3%, Beat mkt rate 57.1%

120 days after: historical avg +35.4%

20-day +14.3%
60-day +14.1%
120-day +35.4%
20-day
60-day
120-day
Win
71.4%
57.1%
57.1%
Sample
7
7
7
Median
+10.6%
+21.3%
+39.1%
Excess
+12.7%
+13.2%
+33.3%
Beat mkt rate
71.4%
57.1%
57.1%

Over 7 occurrences, 120-day forward avg gained 35.4%, beat the market by 33.3 pts; win rate 57.1%.

EPS surprise beat

Active · now 71.4%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
17 historical occurrences (since 2019-11-06)

Average forward return after EPS surprise beat

20-day: Win 68.8%, Sample 16, Median +8.8%, Excess +12.4%, Beat mkt rate 68.8%

60-day: Win 68.8%, Sample 16, Median +14.4%, Excess +10.0%, Beat mkt rate 62.5%

120-day: Win 56.2%, Sample 16, Median +14.6%, Excess +14.0%, Beat mkt rate 56.2%

120 days after: historical avg +24.9%

20-day +15.1%
60-day +16.3%
120-day +24.9%
20-day
60-day
120-day
Win
68.8%
68.8%
56.2%
Sample
16
16
16
Median
+8.8%
+14.4%
+14.6%
Excess
+12.4%
+10.0%
+14.0%
Beat mkt rate
68.8%
62.5%
56.2%

Over 16 occurrences, 120-day forward avg gained 24.9%, beat the market by 14.0 pts; win rate 56.2%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 100,388 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.36%, a 58.3% positive-return rate, and +3.02 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 times historically; 60-day forward avg +9.7%, win rate 75.0%, beating the market by +5.4 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

12 times historically; 60-day forward avg +13.1%, win rate 58.3%, beating the market by +9.5 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.